ESSA is currently conducting a monotherapy Phase 1 open-label clinical trial evaluating the safety, pharmacokinetics, and anti-tumor activity of EPI-7386, an investigational first-in-class N-terminal domain androgen receptor inhibitor, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

For detailed information on the ongoing trial for mCRPC patients, please visit
clinicaltrials.gov.

ESSA is also planning a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination of EPI-7386 and enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies.

More information will be available once the trial has initiated.